NR3C2 and hydrops fetalis: The future TRED-HF 2 study (NCT06091475)39 will explore the withdrawal of mineralocorticoid receptor antagonists and/or sodium–glucose cotransporter 2 inhibitors, while ACE inhibitors and beta-blockers continue, in DCM patients with HFrEFrem.